Not known Details About Ceftriaxone
MI-CP151 was a section 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre analyze to evaluate many intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Principal trial aims ended up To judge the protection and tolerability of sifalimumab in dermatomyositis or polymyosit